CTAD 2025 Conference Dates: November 6-9, 2025
Location: San Diego Convention Center, California, USA
Organizer: CTAD (Clinical Trials on Alzheimer's Disease)
Website: [ctad-alzheimer.com](https://ctad-alzheimer.com)
Overview
flowchart TD
events_ctad_2025["CTAD 2025 Conference"]
events_ctad_2025_1["Conference"]
events_ctad_2025 -->|"related to"| events_ctad_2025_1
style events_ctad_2025_1 fill:#81c784,stroke:#333,color:#000
events_ctad_2025_2["Dates"]
events_ctad_2025 -->|"related to"| events_ctad_2025_2
style events_ctad_2025_2 fill:#81c784,stroke:#333,color:#000
events_ctad_2025_3["November"]
events_ctad_2025 -->|"related to"| events_ctad_2025_3
style events_ctad_2025_3 fill:#81c784,stroke:#333,color:#000
events_ctad_2025_4["Location"]
events_ctad_2025 -->|"related to"| events_ctad_2025_4
style events_ctad_2025_4 fill:#81c784,stroke:#333,color:#000
style events_ctad_2025 fill:#4fc3f7,stroke:#333,color:#000
CTAD 2025 was held in San Diego, California, presenting the latest clinical trial results in [Alzheimer's disease](/diseases/alzheimers-disease) research. The conference is the premier venue for presenting Phase 2 and Phase 3 clinical trial data, bringing together academic researchers, pharmaceutical companies, and regulatory agencies["@ctad2025"].
Key Focus Areas
Anti-Amyloid Therapies CTAD 2025 featured extensive data on anti-amyloid monoclonal antibodies:
...
CTAD 2025 Conference Dates: November 6-9, 2025
Location: San Diego Convention Center, California, USA
Organizer: CTAD (Clinical Trials on Alzheimer's Disease)
Website: [ctad-alzheimer.com](https://ctad-alzheimer.com)
Overview
Mermaid diagram (expand to render)
CTAD 2025 was held in San Diego, California, presenting the latest clinical trial results in [Alzheimer's disease](/diseases/alzheimers-disease) research. The conference is the premier venue for presenting Phase 2 and Phase 3 clinical trial data, bringing together academic researchers, pharmaceutical companies, and regulatory agencies["@ctad2025"].
Key Focus Areas
Anti-Amyloid Therapies CTAD 2025 featured extensive data on anti-amyloid monoclonal antibodies:
[Lecanemab](/entities/lecanemab) ([Leqembi](/drugs/leqembi)) — CLARITY-AD long-term follow-up data[Donanemab](/entities/donanemab) ([Kisunla](/drugs/kisunla)) — TRAILBLAZER-ALZ 2 extended outcomesAnti-amyloid next-generation antibodies — Novel binding profiles and safety dataCombination approaches — Anti-amyloid with [tau](/proteins/tau) or neuroinflammation targetsAnti-Tau Approaches Tau-targeted therapies were a major focus:
Anti-tau antibodies — Multiple Phase 2/3 programsTau aggregation inhibitors — Small molecule programsTau PET imaging correlations with clinical outcomesTau downstream effects — Synaptic function and neuronal lossBiomarker-Driven Trials The integration of biomarkers into clinical trials was prominently featured:
Blood-based biomarkers for patient selection and endpoint assessment[p-tau217](/biomarkers/p-tau-217) as a surrogate endpointAmyloid PET standardization and quantificationNeurodegeneration markers ([NfL](/biomarkers/neurofilament-light-chain-nfl), t-tau)Prevention Trials Updates from Alzheimer's prevention initiatives:
Dominantly Inherited Alzheimer Network (DIAN) trialsAlzheimer's Prevention Initiative (API) updatesA4 Study (Anti-Amyloid in Asymptomatic Alzheimer's)Risk reduction trials in sporadic ADNovel Trial Designs Innovative approaches to clinical trial methodology:
Platform trials for efficient drug testingAdaptive designs in late-stage trialsDigital endpoints and remote monitoringDiversity in clinical trials strategiesNotable Sessions
Late-Breaking Oral Presentations
Phase 3 trial results from major pharmaceutical companies
Novel therapeutic agent first-in-human data
Regulatory pathway discussions
Focused Symposia
"Lessons Learned from Anti-Amyloid Trials" — Optimizing future studies"Tau as a Therapeutic Target" — Current status and future directions"Biomarkers as Surrogate Endpoints" — Regulatory perspectives"Clinical Outcome Assessment" — Cognitive and functional measuresWorkshops
Statistical Methods for Alzheimer's clinical trialsClinical Operations in diverse populationsData Sharing and collaborative analysesIndustry Presence CTAD 2025 featured presentations from leading pharmaceutical and biotechnology companies:
Eisai/ Biogen — Leqembi development programEli Lilly — Donanemab and other pipeline programsRoche/ Genentech — Anti-amyloid and anti-tau programsJohnson & Johnson — Neuroscience pipelineAbbVie — Neurodegeneration portfolioAxon Neuroscience — Tau vaccine programVenue: San Diego
San Diego Convention Center Located in downtown San Diego, the convention center provides state-of-the-art facilities for clinical presentations and poster sessions.
San Diego Biotechnology Hub San Diego is home to a thriving biotechnology community:
UC San Diego — Leading Alzheimer's research centerScripps Research Institute — Drug discovery expertiseSanford Burnham Prebys — Neurobiology researchMultiple biotechnology companies — Alzheimer's drug developmentResearch Collaboration San Diego has established itself as a major center for Alzheimer's clinical research:
Multiple memory clinics and research centers
Strong academic-industry partnerships
Diverse patient populations for clinical trials
[CTAD 2026](/events/ctad-2026) — Boston, USA
[AAIC 2025](/events/aaic-2025) — San Diego, USA
[AD/PD 2025](/events/adpd-2025) — Vienna, Austria
See Also
[Conference Index](/events/conference-index)
[CTAD Conference](/events/ctad)
[Alzheimer's Disease Clinical Trials](/diseases/alzheimers-disease#clinical-trials)
[Lecanemab](/drugs/leqembi)
[Donanemab](/drugs/kisunla)
References
Unknown, CTAD 2025 Official Website (2025)
[Aisen PS, et al., Tau targeting therapies in Alzheimer's disease. Nat Rev Neurol. 2024 (2024)](https://doi.org/10.1038/s41582-024-00867-9)
[Cummings J, et al., Alzheimer's disease drug development pipeline 2024. Alzheimer's Dement. 2024 (2024)](https://doi.org/10.1002/alz.13809)
[Tahami Monfarad SA, et al., Clinical trials update from CTAD 2024. J Prev Alzheimers Dis. 2024 (2024)](https://doi.org/10.14283/jpad.2024.156)
[Cummings J, et al., Alzheimer's disease drug development pipeline 2023. Alzheimer's Dement. 2023 (2023)](https://doi.org/10.1002/alz.12962) Show full description